The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack

Trial Profile

The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Insulin resistance; Myocardial infarction; Stroke
  • Focus Therapeutic Use
  • Acronyms IRIS
  • Most Recent Events

    • 28 Feb 2017 Results of a secondary analysis investigating the effects of pioglitazone on acute coronary syndromes (ACS) (MI and unstable angina) among IRIS participants, published in the Circulation.
    • 24 Feb 2017 Results (N=3707) presented at the 42nd International Stroke Conference.
    • 14 Jun 2016 Results from this trial were presented at the American Diabetes Association's 76th Scientific Sessions, according to an American Diabetes Association media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top